Publication | Closed Access

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

End-of-study ResultsBreast OncologyMedicineClinical TrialsPathologyBreast CancerCancer TreatmentOncologyRadiation OncologyMolecular OncologyHealth Sciences